Avanos Medical (AVNS) Reiterated at Market Perform by Citizens: Much to Look at in 2026

Citizens analyst Daniel Stauder reiterated a Market Perform rating on Avanos Medical (NYSE: AVNS).

The analyst commented, "We reiterate our Market Perform rating on Avanos Medical and highlight several recent events and high-level, company-specific themes to look for in 2026 and beyond. Recall, at the beginning of 2025, AVNS announced a leadership change with the appointment of Dave Pacitti (April 2025) as the company's new CEO. Through the first year of his tenure, management has refocused its strategic imperatives to strengthen execution and "position the company for the next phase of growth". With this in mind, Avanos recently provided an initial broad outline for its new long-term financial goal for ~$1 bln in revenue by 2030 (~$700 mln expected in 2025)."

For an analyst ratings summary and ratings history on Avanos Medical click here. For more ratings news on Avanos Medical click here.

Shares of Avanos Medical closed at $13.42 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy